- Home
- MPLN vs GNLX Comparison
MPLN vs GNLX Comparison
Compare MPLN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPLN
- GNLX
- Stock Information
- Founded
- MPLN 1980
- GNLX 2001
- Country
- MPLN United States
- GNLX United States
- Employees
- MPLN N/A
- GNLX N/A
- Industry
- MPLN Business Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MPLN Consumer Discretionary
- GNLX Health Care
- Exchange
- MPLN Nasdaq
- GNLX Nasdaq
- Market Cap
- MPLN 99.9M
- GNLX 103.6M
- IPO Year
- MPLN N/A
- GNLX 2023
- Fundamental
- Price
- MPLN $7.00
- GNLX $2.55
- Analyst Decision
- MPLN Hold
- GNLX Strong Buy
- Analyst Count
- MPLN 2
- GNLX 4
- Target Price
- MPLN $25.00
- GNLX $18.25
- AVG Volume (30 Days)
- MPLN 84.7K
- GNLX 185.6K
- Earning Date
- MPLN 11-05-2024
- GNLX 11-14-2024
- Dividend Yield
- MPLN N/A
- GNLX N/A
- EPS Growth
- MPLN N/A
- GNLX N/A
- EPS
- MPLN N/A
- GNLX N/A
- Revenue
- MPLN $942,614,000.00
- GNLX $8,000.00
- Revenue This Year
- MPLN N/A
- GNLX N/A
- Revenue Next Year
- MPLN $1.07
- GNLX N/A
- P/E Ratio
- MPLN N/A
- GNLX N/A
- Revenue Growth
- MPLN N/A
- GNLX N/A
- 52 Week Low
- MPLN $4.80
- GNLX $1.60
- 52 Week High
- MPLN $69.20
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- MPLN 41.66
- GNLX 44.80
- Support Level
- MPLN $4.80
- GNLX $2.34
- Resistance Level
- MPLN $9.15
- GNLX $3.07
- Average True Range (ATR)
- MPLN 0.91
- GNLX 0.27
- MACD
- MPLN -0.14
- GNLX -0.07
- Stochastic Oscillator
- MPLN 49.89
- GNLX 22.68
About MPLN MultiPlan Corporation
MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry. The company interprets clients' needs and customizes solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.